Appia Bio
David Baltimore, PhD, is president emeritus and distinguished professor of biology at California Institute of Technology (Caltech). Dr. Baltimore has been involved in the development of American biotechnology since the 1970s. He has helped found numerous companies, most recently Calimmune and Immune Design, and presently serves on the boards of directors at Regulus Therapeutics and the Broad Institute. He is also a member of numerous scientific advisory boards, including Amgen, the Broad Institute, Ragon Institute, and Regulus. Dr. Baltimore has served as president and chair of the American Association for the Advancement of Science and was named a fellow of the American Association for Cancer Research. In 1975, he was awarded the Nobel Prize in Physiology or Medicine for his research into viral replication that provided the key to understanding the life cycle of retroviruses. He earned his PhD from Rockefeller University.
This person is not in the org chart
This person is not in any offices
Appia Bio
Appia Bio is an early-stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).